MICA and sarcoma: Different combinations of NK cell-activating ligands such as MICA/B ULBP1/2/3/5, CD155, and CD112 are known to be expressed on both primary sarcoma samples and cell lines, allowing for NK cell cytotoxicity [41,42,43,44,45].